LMT Lombard Med.Tec

RNS Number:2018A
Lombard Medical Technologies PLC
13 July 2007

  Lombard Medical Announces First US Case in a Patient with a High-angle-neck
                        Aneurysm Using "Gen II" AorfixTM



London, UK, 13 July 2007 - Lombard Medical Technologies PLC ("Lombard Medical")
today announces that it has successfully performed the first endovascular stent
graft implantation to treat an abdominal aortic aneurysm ("AAA") with a neck
angle of greater than 60degrees in its pivotal US clinical trial for AorfixTM.
The procedure was performed using the improved version of AorfixTM ("Gen II")
approved by the FDA for the clinical trial in April.



The case was the first to be performed under the revised protocol for the
clinical trial that extends the entry criteria to add patients with aneurysm
neck angles from 60degrees to 90degrees.  Neck angulations of this severity have
no licensed endoluminal treatment in the US and if successful, the trial will
result in a unique label claim for AorfixTM.  The FDA gave conditional approval
for the extended protocol this May.



It is estimated that between 10 and 15% of patients have aneurysms with neck
angles over 60degrees representing a significant segment of the total AAA market
forecast to be worth almost $1bn by the end of the decade.



Dr Mark Fillinger, who performed the procedure at Dartmouth Hitchcock Medical
Center, Lebanon, NH, said:



"The disease in this case had caused a sharp angulation in the aorta to 79
degrees, which the trial is specifically designed to address. In addition, there
was a less-than-ideal cone shape to the attachment site, and a sharp angulation
above the attachment site as well.  I do not believe that any other available
stent graft could have treated this aneurysm properly, and the patient had been
waiting for AorfixTM to become available in this clinical trial.  We are very
pleased with the result and so is the patient."



Alistair Taylor, Executive Chairman, said:



"We are delighted with the outcome of this case.  It demonstrates the ability of
the Gen II device to expand endovascular treatment of AAA to this large
sub-group of patients and it indicates the potential for the product in the
United States.  We expect that our clinical trial will accelerate with the
expanded protocol using this exciting device."



Enquiries:


Lombard Medical Technologies PLC                              Tel: 01235 750 800
Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer
Tim Hall, Finance Director

Financial Dynamics                                            Tel: 020 7831 3113
David Yates/John Gilbert



Notes to editors



About Lombard Medical

Lombard Medical Technologies PLC is a medical devices group developing stent
grafts and other medical products for use in the treatment of vascular disease.
The Company's lead product, AorfixTM, is a stent graft for the treatment of
aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated,
may rupture and cause death.  Abdominal and thoracic aortic aneurysms are the
13th largest cause of death in the US and the market is estimated to be worth
approximately US$2 billion by 2010.  AorfixTM is currently being commercialised
in the EU, with US clinical trials having commenced during 2006.   The Company's
Polymer Coatings Division primarily develops polymer coatings for use in
drug-eluting stents and has a number of research collaborations developing novel
products for this $6bn market.



The Company, headquartered in Oxfordshire, with operations in Yorkshire and
Boston, USA, employs over 90 people.



Further background on the Company can be found at www.lombardmedical.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCIIFLADEIVLID

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024